[HTML][HTML] Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence

S Darici, H Alkhaldi, G Horne, HG Jørgensen… - Journal of Clinical …, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

Removing the boundaries: palliative care for patients with heart failure

G Horne, S Payne - Palliative medicine, 2004 - journals.sagepub.com
Aim: This study aimed to explore the experiences of patients with severe heart failure and
identify their needs for palliative care. Method: A qualitative design was chosen …

BRD 4 associates with p53 in DNMT 3A‐mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ 1

HJS Stewart, GA Horne, S Bastow… - Cancer …, 2013 - Wiley Online Library
The bromodomain and extra terminal (BET) family protein bromodomain containing protein
4 (BRD 4) is an epigenetic regulator recently identified as a therapeutic target for several …

Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells

S Darici, M Zavatti, L Braglia, B Accordi… - Advances in Biological …, 2021 - Elsevier
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by
a heterogeneous genetic landscape and complex clonal evolution, with poor outcomes …

Maintaining integrity in the face of death: a grounded theory to explain the perspectives of people affected by lung cancer about the expression of wishes for end of life …

G Horne, J Seymour, S Payne - International journal of nursing studies, 2012 - Elsevier
BACKGROUND: An emphasis on patient choice in health and social care underpins a
growing interest in advance care planning. Few studies have explored the views and …

[HTML][HTML] CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

R Kinstrie, GA Horne, H Morrison, D Irvine, C Munje… - Leukemia, 2020 - nature.com
The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of
chronic myeloid leukemia (CML). A major clinical aim remains the identification and …

Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1

GA Horne, HJS Stewart, J Dickson… - Stem Cells and …, 2015 - liebertpub.com
Embryonic stem cells (ESCs) are maintained in an undifferentiated state through expression
of the core transcriptional factors Nanog, Oct4, and Sox2. However, the epigenetic …

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia …

M Copland, D Slade, G McIlroy, G Horne… - The Lancet …, 2022 - thelancet.com
Background Outcomes for patients with blast-phase chronic myeloid leukaemia are poor.
Long-term survival depends on reaching a second chronic phase, followed by allogeneic …

Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments

GA Horne, M Copland - Expert Opinion on Drug Discovery, 2017 - Taylor & Francis
Introduction: Self-renewal is considered a defining property of stem cells. Self-renewal is
essential in embryogenesis and normal tissue repair and homeostasis. However, in cancer …

Advance care planning for patients with inoperable lung cancer

G Horne, J Seymour… - International journal of …, 2006 - magonlinelibrary.com
Aim To develop and pilot an advance care planning (ACP) intervention for lung cancer
nurses to use in discussing end-of-life preferences and choices for care with patients …